http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
-
Pfizer (PFE) Announces FDA Approval of ABRYSVO for RSV in Older Adults
-
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
-
Seagen (SGEN) Stockholders Approve Acquisition by Pfizer (PFE)
-
Pfizer (PFE) announces Phase 3 BASIS clinical trial for marstacimab has met its primary endpoints
-
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
-
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
-
Pfizer's (PFE) PAXLOVID Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
-
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
-
Pfizer (PFE) Reports AdCom Vote in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
-
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
-
Pfizer (PFE) Announces Proposed Notes Offering
-
Pfizer Announces Proposed Notes Offering
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
-
Pfizer (PFE) Announces U.S. FDA Approves PREVNAR 20, its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
-
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
-
Pfizer Declares Second-Quarter 2023 Dividend
-
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
-
Pfizer (PFE) announced FDA accepts sNDA for BRAFTOVI + MEKTOVI
-
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
-
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
-
Pfizer (PFE) Confirms FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID
-
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
-
Pfizer (PFE) Acquires Seagen (SGEN) for $43B or $229/sh
-
Pfizer Invests $43 Billion to Battle Cancer
-
Pfizer Invests $43 Billion to Battle Cancer
-
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
-
Pfizer (PFE) Announces Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
-
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer's (PFE) Elranatamab Granted FDA and EMA Filing Acceptance
-
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
-
Pfizer (PFE) Announces FDA Acceptance of Application for Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
-
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
-
Pfizer (PFE) and Valneva (VALN) Issue Update on Phase 3 Clinical Trial of VLA15
-
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
-
Pfizer (PFE) Announces Publication of Phase 3 Data for Zavegepant
-
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
-
Pfizer (PFE) Announces FDA Approves Supplemental New Drug Application for CIBINQO
-
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) Expands ‘An Accord for a Healthier World’ Product Offering
-
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
-
Pfizer (PFE) Announces FDA Acceptance for Priority Review of sBLA for 20vPnC
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) Reports Positive Top-Line Results from Phase 3 Study of fidanacogene elaparvovec
-
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
-
Pfizer (PFE) Announces FDA Acceptance of BLA for MenABCWY

